Weight Loss Peptides Explained: Semaglutide, Tirzepatide, and What Actually Works
GLP-1 and dual-agonist peptides have changed weight management. Here is an evidence-based, clinician-reviewed look at how they work, who they are for, and what to expect.
Weight loss peptides — primarily GLP-1 receptor agonists like semaglutide and dual GIP/GLP-1 agonists like tirzepatide — represent the most significant advance in obesity treatment in a generation. For patients who have struggled with diet and exercise alone, these medications offer clinically meaningful weight loss supported by large, randomized trials. But they are not magic, and understanding how they work is the first step to using them well.
This article is educational and is not medical advice. Prescription weight-loss medications should only be prescribed by a licensed clinician after an individualized evaluation. Individual results vary.
How GLP-1 and Dual-Agonist Peptides Work
Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone released by the gut after eating. It does three things: it stimulates insulin release in response to meals, it suppresses glucagon (which raises blood sugar), and it slows gastric emptying so you feel full longer. GLP-1 also acts on appetite centers in the brain to reduce hunger.1
Medications like semaglutide mimic this hormone but last much longer in the body — a once-weekly injection maintains therapeutic levels. Tirzepatide goes a step further by targeting two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), which is why it tends to produce greater average weight loss in head-to-head comparisons.2
Semaglutide vs. Tirzepatide: What the Evidence Shows
Both medications have been studied extensively. In pivotal trials, semaglutide produced mean weight loss of roughly 15% of body weight over 68 weeks at the maintenance dose, while tirzepatide produced mean losses approaching 20% or more over a similar timeframe.2,3 Importantly, these are averages — individual results vary based on dose, adherence, diet, and baseline factors.
- Semaglutide: A GLP-1 agonist available in branded and compounded forms. Well-studied, with a long safety record in diabetes care.
- Tirzepatide: A dual GIP/GLP-1 agonist with greater average weight loss in trials, now widely used for chronic weight management.
Choosing between them is a clinical decision based on your history, goals, tolerance, and budget. PRBLY connects patients with clinicians who prescribe both — start with the Weight Loss pathway to see your options.
What to Expect During Treatment
Peptide weight-loss protocols almost always start low and titrate up. This "step-up" dosing reduces gastrointestinal side effects, which are the most common reason people discontinue early. Typical side effects include nausea, constipation or diarrhea, and reduced appetite — most resolve as the body adjusts.
Weight loss is not linear. Many patients see rapid early loss, a plateau, then resumed loss as the dose increases. Clinician oversight matters here: dose adjustments, side-effect management, and monitoring of muscle mass and nutrition are what separate a safe, effective protocol from a risky one.
Who These Medications Are For
GLP-1 and dual-agonist peptides are generally indicated for patients with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like hypertension, type 2 diabetes, or sleep apnea. They are not intended for cosmetic weight loss or people at a healthy weight. A clinician will determine eligibility based on your full history, not just your BMI.
Cost and Access
Cost is the most common barrier to GLP-1 therapy. Branded medications can be expensive and are not always covered by insurance for weight-loss indications. Compounded versions and negotiated-rate programs — like the ones PRBLY facilitates — can make treatment substantially more affordable. The key is comparing the total cost of care, not just a headline price. See how PRBLY helps patients access negotiated weight-loss pricing.
Why E-E-A-T Matters in Weight-Loss Content
Health and medical content is held to Google's highest quality standard under the E-E-A-T framework.4 That is why every PRBLY weight-loss article is reviewed by a licensed clinician, cites primary sources, and avoids unsubstantiated outcome claims. Patients deserve information they can trust before they make a medical decision.
The Bottom Line
Weight loss peptides are a genuine breakthrough, but they work best as part of a clinician-supervised protocol — not a self-directed experiment. Understanding the mechanism, the evidence, and the realistic expectations is what turns a promising medication into a result. Probably fine. Not good enough.
Sources & Citations
- Drucker DJ. The biology of incretin hormones. Cell Metabolism.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
- Google. Search Quality Evaluator Guidelines; E-E-A-T for medical content. Google Search Central.
About the PRBLY Medical Team
PRBLY's editorial content is reviewed by licensed healthcare professionals to ensure medical accuracy, clarity, and balance. Our team breaks down treatments, medications, and health topics in plain language so you can understand your options and make more informed decisions.
This article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about your specific situation.